Geographic Atrophy (GA) Market Size, Share & Segmentation By Age Group (Above 60 Years, above 75 Years), By Diagnosis (Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)), By Therapeutic Agents Clinical Phase (Late-stage (Phase III), Phase II, Phase I, Pre-clinical stage & Discovery candidates), by Regions and Global Forecast 2023-2030

Report Scope & Overview:

Geographic Atrophy (GA) Market expected to grow at a CAGR of 7.2% over the forecast period 2023-2030. Geographic atrophy, a severe form of age-related macular degeneration (AMD), causes the macula to continuously deteriorate over time. This syndrome is characterised by extensive atrophy of the choriocapillaris, outer retinal tissue, and retinal pigment epithelium. Typically, it begins in the perifoveal area and moves into the fovea over time, resulting in central scotomas and irreversible vision loss.

MARKET DYNAMICS

DRIVERS

• Increasing number of seniors

• Geographic atrophy is becoming more common in every country.

• Pharmaceutical and biopharmaceutical companies are investing more money in research and development.

RESTRAINTS

• Medicines used to treat geographic atrophy are subject to strict government controls.

• Geographic atrophy and other ocular illnesses are not widely known in less developed nations.

OPPORTUNITIES

• The creation of novel treatments for geographic atrophy

• Utilizing gene therapy to cure geographic atrophy is an example of technology.

CHALLENGES

• Players in the geographic atrophy industry may have difficulties because to the rigorous rules being enforced by governments around the world.

IMPACT OF COVID-19

With the COVID-19 outbreak and the significant financial losses suffered by several industries globally, including the healthcare sector, the year 2020 took an unexpected turn. The COVID-19 epidemic made things worse by impacting, among other areas, the healthcare sector and upsetting supply networks. The pandemic has hurt the geographic atrophy market since the vendors have had to close their manufacturing facilities or keep them operating at considerably lower production levels in order to stop the new coronavirus from spreading.

On the plus side, the market for geographic atrophy might experience significant growth over the next years with the easing of the lockdown and trade restrictions.

VALUE CHAIN ANALYSIS

The geographic atrophy (GA) market is anticipated to grow significantly over the forecast period, which can be attributable to factors like an increase in the number of companies who are all moving forward to introduce novel pharmacological molecules for the treatment of geographic atrophy. In addition, the market is expanding as a result of an increase in the demand for research funding for the creation of novel technologies to cure geographic atrophy. The geographic atrophy industry's value chain analysis is divided into four main sections that start with R&D and product creation, go through manufacture, distribution, and post-marketing surveillance.

By Age Group

Adults over the age of 60 have an increased chance of acquiring a number of eye conditions that can impair vision, including geographic atrophy, cataracts, diabetic retinopathy, age-related macular degeneration (AMD), dry eye, glaucoma, and others.

Sharp and central vision are reduced by geographic atrophy, an age-related eye disorder. Additionally, geographic atrophy is becoming more common in people over 75 due to age-related factors. Geographic atrophy, for instance, affects 1.3 percent of people between the ages of 75 and 84, rising to about 22 percent by the age of 90, as per the Retina Study Group of Portugal.

By Diagnosis

It has been shown that fundus autofluorescence imaging can help in geographic atrophy progression prediction. A diagnostic method for locating fluorophores in the human eye is fundus autofluorescence imaging (FAF). Chemical compounds known as fluorophores glow when they are exposed to the right kind of light. Additionally, fundus autofluorescence, the industry-standard diagnostic imaging technique, is routinely used to visualise the retinal pigment epithelium (RPE) in geographic atrophy.

The microvasculature of the retina and choroid can now be seen using optical coherence tomography angiography (OCT-A), a non-invasive method. Numerous retinal disorders, including geographic atrophy, diabetic retinopathy, vascular occlusions, dry and wet age-related macular degeneration, and others, can be diagnosed and understood with its help.

Local electroretinogram (ERG) responses from many retinal regions can be captured simultaneously using the multifocal electroretinogram (mfERG) approach. Multifocal electroretinography applies light stimulation to the retina in patterns while an electrode records photoreceptor signalling. By varying the light stimulation, the retina is mapped with details on its functionality and sensitivity. Reading ability and contrast sensitivity should be employed to fully measure visual impairment in geographic atrophy.

By Therapeutic Agents Clinical Phase

According to preliminary data from earlier trials, the goal of phase III clinical trials is to confirm that the medication is secure, beneficial, and efficient for the specified indication. To determine whether a novel treatment or drug combination is superior to or equivalent to the present standard of care, phase III clinical trials are used.

If a new medicine is determined to be safe in phase I clinical trials, a phase II clinical trial is done. Numerous clinical research investigates whether recipients of a novel treatment outlive those who do not. Community hospitals or even physician offices may conduct phase II investigations.

Phase I studies are carried out to ascertain the highest dosage of a novel drug that may be supplied safely without producing severe side effects. Even if the drug has been researched in lab and on animals, it is impossible to foresee the adverse effects in people. The best way to deliver the new medicine is also determined by these investigations. Phase I studies also examine how the medicine affects the body and how the body interacts with the drug.

The pre-clinical stage of drug development, sometimes referred to as pre-clinical research or nonclinical investigations, is a phase that takes place before clinical trials involving humans and iterative testing, gathers crucial feasibility, and drug safety data, typically in laboratory animals.

COMPETITIVE LANDSCAPE

Some of the major key players of Geographic Atrophy (GA) Market are as follows:

AstraZeneca plc, Gyroscope Therapeutics Limited, Hoffmann-La Roche AG, Apellis Pharmaceuticals, Inc., Iveric Bio, Gensight Biologics SA, Stealth BioTherapeutics, Allegro Ophthalmics, LLC, Regenerative Patch Technologies, LLC, Genentech, Inc., Alkeus Pharmaceuticals, Inc., NGM Biopharmaceuticals Inc., Hemera Biosciences LLC, and other players.

MARKET SEGMENT

By Age Group

• Above 60 Years

• Above 75 Years

By Diagnosis

• Fundus Autofluorescence (FAF)

• Optical Coherence Tomography Angiography (OCT-A)

• Multifocal Electroretinography (mfERG)

By Therapeutic Agents Clinical Phase

• Late-stage (Phase III)

• Phase II

• Phase I

• Pre-clinical stage & Discovery candidates

REGIONAL ANALYSIS

Geographic atrophy is most prevalent in North America because to rising healthcare spending and the existence of well-known competitors there, such as Iveric Bio, Alkeus Pharmaceuticals Inc., Apellis Pharmaceuticals, Inc., and others. In addition, the growing number of geographic atrophy cases in the area and the growing number of government activities addressing geographic atrophy in the area may help to advance the market position.

Geographic atrophy sales in Europe have been growing at an astounding rate as a result of an ageing population, increased demand for technologically sophisticated treatments, and increased R&D spending in the biopharmaceutical sector. Due to the leading competitors' rapid penetration of industrialized nations like Germany, France, and the UK, the market expansion rate in Europe is fairly large. Improvements in the treatment of GA have been made possible by high-level and active research and development operations in these nations.

REGIONAL COVERAGE:

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • The Netherlands

  • Rest of Europe

• Asia-Pacific

  • Japan

  • south Korea

  • China

  • India

  • Australia

  • Rest of Asia-Pacific

• The Middle East & Africa

  • Israel

  • UAE

  • South Africa

  • Rest of Middle East & Africa

• Latin America

  • Brazil

  • Argentina

  • Rest of Latin America

Frequently Asked Questions (FAQ) :